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Till min älskade lillebror, jag önskar att du var här… 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
På senare år har man börjat betrakta cancer som ett organ. Precis som vanliga organ i 
kroppen byggs tumörer upp av flera olika celltyper t.ex. stödjeceller kallade fibroblaster 
samt blodkärl. Alla de olika celltyperna i tumören kommunicerar med varandra genom 
signaleringsmolekyler. 
 
Målinriktade farmakologiska behandlingar har på senare tid blivit introducerade som en 
del av behandlingen av vissa former av cancer. Förhoppningen är att man kan reducera 
biverkningarna av de nuvarande behandlingarna genom att behandla flera komponenter 
och signaleringsvägar samtidigt. Denna avhandling har studerat cancer-associerade 
fibroblaster (CAF) och blodkärl i tumörer för att identifiera mekanismer som skulle 
kunna vara målet för nya målinriktade behandlingar.  
 
Vi har studerat vad som händer när en speciell form av platelet-derived growth factor 
(PDGF), PDGF-CC är uttryckt av tumörcellerna. PDGF-CC kan rekrytera CAF till 
tumören och dessa i sin tur påverkar blodkärlsbildningen så att nya blodkärl bildas, 
vilket gör att tumören kan växa snabbare. Vi har också sett att när PDGF-CC uttrycks 
av tumörcellerna i bröstcancer korrelerar det med en kortare överlevnad. Antikroppar 
kan användas för att blockera signalerna som proteinerna medierar. Vi har utvecklat en 
sådan antikropp mot PDGF-CC. I en musmodell av bröstcancer växer tumörer som 
behandlas med denna antikropp långsammare.  
 
I två andra studier har vi studerat vad som händer om man reducerar uttrycket av två 
receptorer på cellerna som bygger upp blodkärlen, endoglin och Activin Receptor-Like 
Kinase 1 (ALK1). Tumörer kan anpassa sig till om man tar bort endoglin. Dessa 
tumörer ger dock upphov till fler metastaser. Om man behandlar tumörerna samtidigt 
med en annan blodkärlshämmare så utvecklas inte resistens, således skulle det vara 
intressant att kombinera behandling av dessa två olika signaler samtidigt. Reducerar vi 
ALK1 istället resulterar det i mindre tumörer med färre blodkärl vilket vi föreslår som 
en ny målinriktad behandling av cancer.  
 
ABSTRACT 
 
Cancer is the result of aberrant cells developing into tumor cells that act in concert with 
the micro- and macroenvironment like any other organ in our bodies. The cells and 
molecules of the tumor microenvironment are important contributors to the tumorigenic 
process. However, we are still far from understanding the full complexity and intricate 
molecular interactions that affect the process.  
 
We show that platelet-derived growth factor (PDGF)-CC, expressed by tumor cells, 
recruit cancer-associated fibroblasts (CAFs) to the tumor microenvironment resulting in 
an accelerated tumor growth rate. Among the CAFs, we identify three different 
subclasses by their variable expression of fibroblast specific protein (FSP)-1 and PDGF 
receptor (PDGFR)-α. Two of these subclasses express osteopontin (OPN), which is 
responsible for the increased tumor growth rate. In subsequent studies, we reveal that 
PDGF-CC expression is high in breast cancer and that PDGF-CC presence in epithelial 
cells is an independent prognostic marker for patient survival in a large cohort of 
patients. We also developed a monoclonal antibody for PDGF-CC, which as a 
monotherapy reduces tumor growth rate proving the in vivo efficacy of targeting 
PDGF-CC.  
 
 Transforming growth factor (TGF)-β family members have been attributed complex 
and contradictory effects on angiogenesis. We have studied the effect of ablation of 
endoglin or activin receptor-like kinase 1 (ALK1) in tumor models. Targeting endoglin 
results in adaptation and no effect on tumor growth or vessel density. We do however 
detect increased metastatic seeding as a consequence of endothelial to mesenchymal 
transition (EndMT). Endoglin deficiency prolongs the tumor sensitivity to 
antiangiogenic therapy that otherwise induce resistance. However, pharmacological and 
genetic targeting of ALK1 results in reduction of tumor formation and burden due to 
decrease in the vessel density. Molecular characterization reveals that the combination 
of TGF-β and bone morphogenic protein (BMP)-9 is responsible for inducing 
activation of endothelial cells and angiogenesis.  
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1 INTRODUCTION 
 
Cancer is one of the most common diseases and the lifetime risk of being affected is 
around 40% in the US (ACS, 2007) and Sweden (Åberg, 2010). Despite advances in 
both detection and treatment, the mortality rate in cancer is approximately 20% (ACS, 
2007). The sites most often affected include breast in women and prostate in men 
followed by skin and colon cancer for both genders. In general, tumors arise in 80% of 
the cases from epithelial tissues whereas 19% are leukemias/lymphomas, which are 
derived from the hematopoietic cells. Around 1% of the tumors are sarcomas arising in 
the connective tissue (Weinberg, 2007).  
 
Historically, cancer research has been focused on the tumor cells per se exhibiting traits 
of loss control over cell division with very little attention put on the other cells that are 
present in the vicinity. However, pathologists early recognized that some tumors also 
contained an abundance of other cell types and extracellular matrix (ECM) and there 
were early ideas about the importance of the other components of the tumor. Already in 
1971, Judah Folkman articulated the idea that inhibiting tumor angiogenesis could 
inhibit tumor growth (Folkman, 1971; Kerbel, 1997). In the 1980’s, histological studies 
suggested striking similarities between tumors and wound healing, leading up to the 
proposition that the tumor is able to abuse or exaggerate normal physiological 
processes (Dvorak, 1986). However, only a minute part of cancer research paid 
attention to those areas.  
 
In an attempt to summarize all the conclusions from decades of previous research 
within the cancer field, Hanahan and Weinberg wrote their now classical review 
condensing cancer into six functional capabilities that needed to be acquired in order 
for a tumor to form (Hanahan and Weinberg, 2000). 
 
These capabilities include:  
• self-sufficiency in growth signals 
• insensitivity to anti-growth signals 
• tissue invasion and metastasis 
• limitless replicative potential 
• sustained angiogenesis  
• evasion of apoptosis  
 
Although not explicitly mentioned, the tumor cells themselves are considered to acquire 
all the traits described. 
   
The emerging view of cancer today is that it is a disease built up by several cell types, 
all working in conjunction as any other organ in our body (Radisky et al., 2001), and 
that this organ also has the ability to communicate with the rest of the organism turning 
cancer into a systemic disease. The tumor microenvironment is composed of the cancer 
cells, endothelial cells and pericytes forming the tumor vasculature, several types of 
immune cells, CAFs and the ECM, as well as circulating cells recruited from the bone 
marrow (Joyce, 2005; Pietras and Ostman, 2010). The six hallmarks of cancer do not 
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necessarily need to be acquired by the tumor cells themselves (Pietras and Ostman, 
2010), but can rather be the result of paracrine crosstalk with the tumor stroma. 
Recently, the follow-up of the Hallmarks of Cancer was published. Two new emerging 
hallmarks were included i.e. deregulation of cellular energetics and avoiding immune 
destruction. However, these are not fully characterized and generalized yet, hence the 
label as emerging. They have also included two consequential characteristics that 
facilitate the achievement of hallmarks, tumor-promoting inflammation and genome 
instability and mutation. It is also emphasized that the tumor microenvironment 
contributes to the tumor development and characteristics (Hanahan and Weinberg, 
2011).  
 
1.1 THE TUMOR MICROENVIRONMENT 
The tumor microenvironment was early on considered to be unchanged by the 
tumorigenic process. However, studies have shown that the microenvironment is not 
unchanged during the development of a tumor; it evolves together with the tumor cells 
(Polyak et al., 2009). The microenvironment can also be the driver of tumor 
development. Early experiments where the mammary fat pad was cleared of epithelial 
cells, then irradiated followed by re-transplantation of epithelia reported that the tumor 
number was significantly increased compared to non-irradiated hosts (Barcellos-Hoff 
and Ravani, 2000). Similar results were obtained when irradiated fibroblasts were 
grafted together with weakly tumorigenic pancreatic cells (Ohuchida et al., 2004). In 
addition, injection of tumor cells in p53 knockout mice displayed enhanced tumor 
growth rate (Kiaris et al., 2005). The non-malignant cells and components of the tumor 
microenvironment have implications for cancer prevention, diagnosis and treatment 
(Polyak et al., 2009).   
 
The components of the tumor microenvironment will be discussed briefly below. 
Angiogenesis and fibroblasts will be discussed in more detail, as they are the 
foundation of the work this thesis is based on.  
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Figure 1. The components of the tumor micro- and macroenvironment. 
The tumor microenvironment contains not only tumor cells but also ECM, immune 
cells, CAFs, bone marrow derived cells (BMDC) and the endothelial cells and pericytes 
building up the vasculature. The tumor also communicates over distance recruiting 
cells, in addition to releasing paracrine factors with systemic action and seeding tumor 
cells for metastasis. 
 
	  
1.1.1  ECM 
The ECM consists of a complex mix of glycoproteins, proteoglycans, cytokines and 
growth factors (Aumailley and Gayraud, 1998; Bissell et al., 1982) and provides a 
scaffold for the tissue in order to provide important contextual information. Fibroblasts 
and epithelial cells produce the ECM in collaboration (Bissell and Radisky, 2001). The 
ECM
Secreted  signaling  
molecules
BMDC
CAF
Immune  cell
Pericyte
Endothelial  cell
Tumor  cell
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basement membrane (BM) is a specialized type of ECM lining the epithelium and 
vasculature (Radisky et al., 2001). As the requirements of tissues are different, the 
ECM composition varies accordingly in the healthy situation (Streuli, 1999; Tsai, 
1998). The ECM in tumors is abnormal and may contain components such as tenascin, 
fibronectin and alternative isoforms of laminins (Lohi et al., 1998; Wenk et al., 2000), 
which has implications for the balance of proliferation and apoptosis in the tumor 
(Ramos et al., 1998; Schoenwaelder and Burridge, 1999; Sethi et al., 1999).  The ECM 
in tumors resembles that of a healing wound (Dvorak, 1986).  
 
1.1.2 Inflammation 
Several forms of tumors are associated with chronic inflammation (Joyce, 2005; 
Virchow, 1858). The tumor cells themselves, but also other cell types, e.g. CAFs, 
produce a variety of different chemokines and cytokines that attract components of the 
immune system.  The tumor microenvironment contains neutrophils, dendritic cells, 
eosinophils, mast cells, macrophages and lymphocytes. These cells are able to produce 
cytokines, cytotoxic agents, membrane disruptive agents, as well as a plethora of 
different proteases, angiogenic and lymphangiogenic growth factors (Kuper et al., 
2000; Mantovani et al., 2008; Schoppmann et al., 2002; Wahl and Kleinman, 1998). 
The factors that these immune cells produce affect both tumor cells and the tumor 
micro- and macroenvironment. However, the contribution of the immune system 
component will not be discussed in further detail.  
 
1.1.3 The tumor macroenvironment 
As pointed out earlier, a tumor also has systemic effects. Inflammatory cells are 
recruited from a distance. In addition fibroblasts (discussed below) and to some extent 
probably endothelial cells (Rafii et al., 2002) may also be recruited to the tumor 
microenvironment. These cells are most likely derived from the bone marrow. 
Experimental evidence points to that this is an active recruitment by the tumor that 
produces factors such as TGF-β and OPN that mobilize and recruit cells from a 
distance to the tumor (McAllister et al., 2008; Yang et al., 2008). 
 
Already in 1889 Paget pointed out that tumors metastasized to specific, not random, 
places depending on the primary tumor (Paget, 1989).The spread of tumors through the 
circulation may hold part of the explanation because of the physical limitations it 
presents. However, recent investigations have provided evidence that the site of 
metastasis may be influenced by the primary tumor to create a welcoming 
microenvironment through systemic effects. As proof of principle that the primary 
tumor influences the site of metastasis Lewis Lung carcinoma (LLC) bearing mice 
were injected with medium from B16 melanoma cells and this was enough to redirect 
metastases to sites where they are commonly found for the melanoma model (Kaplan et 
al., 2005). There are data indicating that BMDC are present at the metastatic site before 
arrival of the tumor cells (Wels et al., 2008).  The systemic stimuli, when it comes to 
preparing the metastatic site, and the primary tumor for that matter, does not 
necessarily need to be circulating proteins, microvesicles may also be an important 
factor (Peinado et al., 2011).  Remodeling of the metastatic site through lysyl oxidase, 
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that crosslinks proteins of the ECM, secreted by the tumor may also be an event 
important for a welcoming microenvironment (Psaila and Lyden, 2009).  
  
Certain tumors have the ability to influence growth of otherwise very slow growing 
malignant cells that not consistently form tumors in mice. Using this system, OPN was 
identified as the main stimulus for the mobilization of BMDC that enabled the growth 
of the slow growing malignancy (McAllister et al., 2008). Follow-up experiments 
implicated a desmoplastic stroma, created by fibroblasts at the recipient tumor site, as 
responsible for the increased tumor growth. The fibroblasts were activated by the 
recruited BMDC (Elkabets et al., 2011).  This may also have implications for 
metastasis as the systemic stimuli also influenced growth of metastases (McAllister et 
al., 2008).  
 
1.2 FIBROBLASTS 
Fibroblasts are in general a very heterogeneous population, which originally was, and 
still to a large extent is, identified by the morphological appearance as spindle-shaped 
elongated cells within the ECM and lack of markers suggesting other cell lineages 
(Kalluri and Zeisberg, 2006). There is a large problem with identifying fibroblasts with 
molecular markers as no marker labels all fibroblasts and many markers used are not 
exclusive for fibroblasts (Kalluri and Zeisberg, 2006; Sugimoto et al., 2006).  
 
Fibroblasts are important producers of ECM components as well as highly engaged in 
the remodeling of the scaffold through secretion of proteases. Fibroblast and epithelial 
interactions are important during development for example in breast, skin and lung 
(Hogan and Yingling, 1998; Simian et al., 2001; Sorrell and Caplan, 2009). In addition, 
fibroblasts are instrumental in wound healing. Following fibrin clot formation 
fibroblasts migrate into the clot towards growth factors such as fibroblast growth factor 
(FGF), TGF-β and PDGF. The two latter converts them into activated fibroblasts, 
which apply contractile force closing the wound. The activated fibroblasts go through 
apoptosis during the end stages of wound healing (Darby and Hewitson, 2007). If 
fibroblasts are activated improperly or activation not terminated at the correct time 
point, fibrosis will be induced.  TGF-β signaling, especially non-canonical, has recently 
been suggested as an anti-fibrosis treatment (Rosenbloom et al., 2010).  
 
1.2.1 Fibroblasts in tumors 
The CAF, or sometimes tumor-associated fibroblast, is the most common cell type in 
the tumor stroma and has prominent influences on the tumor development and 
progression. The widest definition of a CAF, that will be used here, is all fibroblasts 
within the tumor stroma, regardless of the activation status as shown by expression of 
myofibroblastic markers (Micke and Ostman, 2004).  As their normal counterparts, 
CAFs come in many different flavours expressing a variety of different molecular 
markers. These identified subpopulations of CAFs express markers such as FSP-1 (also 
S100A4), fibroblast-activated protein (FAP), α-smooth muscle actin (SMA), vimentin 
and PDGF receptor (PDGFR)-α and -β (Micke and Ostman, 2004; Ostman and 
Augsten, 2009; Sugimoto et al., 2006).  Some of these markers also label pericytes, 
smooth muscle cells and macrophages. Hitherto, no marker has been demonstrated to 
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label all CAF subpopulations. This diversity and inconsistency of marker expression 
underlines the heterogeneity of CAFs with regard to their functional properties within 
the tumor microenvironment, just as the normal tissue fibroblasts. 
 
1.2.1.1 Origin of CAFs 
 
In coherence with their heterogeneity, CAFs have been proposed to originate from 
several different sources. All these studies have been performed in mouse models. 
Resident tissue fibroblasts have been shown to be a source of CAFs (Micke and 
Ostman, 2004). Transdifferentiation of epithelial and endothelial cells into 
mesenchymal cells is another recruitment path. Epithelial to mesenchymal transition 
(EMT) as a source of fibroblasts has been shown in fibrosis (Iwano et al., 2002) but 
also in tumors where similar genetic changes have been detected in tumor cells and 
CAFs (Ellsworth et al., 2004; Fukino et al., 2004; Kurose et al., 2002; Petersen et al., 
2003; Tuhkanen et al., 2004). Zeisberg and colleagues have shown that endothelial 
cells in two different tumor models down regulate CD31 concomitant with up 
regulation of FSP-1 in vivo.  Similar changes were recorded in vitro following TGF-β 
stimulation of primary endothelial cells (Zeisberg et al., 2007). Less established is 
transdifferentiation of other cells in the tumor stroma, including vascular mural cells 
and adipocytes, which may be an explanation for the appearance of pericyte markers on 
CAFs (Anderberg and Pietras, 2009; Ronnov-Jessen et al., 1995; Xing et al., 2010). 
The CAFs can also be recruited systemically in the form of mesenchymal stem cells 
(MSC) and bone marrow precursor cells. This has been shown through transplantation 
experiments where labeled bone marrow cells are detected in the tumor stroma as CAFs 
(Direkze et al., 2004; Ishii et al., 2005; Sangai et al., 2005). These means of recruitment 
of CAFs are not mutually exclusive and several processes are most likely involved in 
contributing to the diverse CAF populations seen in experimental tumors. The origin of 
CAFs in human tumors has not been an area of research that has been intensely 
investigated. 
 
1.2.1.2 The contribution of CAFs to the malignant phenotype 
 
Early experiments in vitro and in mouse models have confirmed the importance of 
CAFs as active players in the tumorigenic process. These experiments indicated that 
CAFs are functionally different in this aspect from normal fibroblasts, which strives to 
normalize the malignancy (Barcellos-Hoff and Ravani, 2000; Hayward et al., 2001; 
Olumi et al., 1999). 
 
CAFs produce several growth factors from a number of families that act in an autocrine 
or paracrine fashion in the tumor microenvironment. These include the FGF family, the 
insulin growth factor family, the epithelial growth factor family, hepatocyte growth 
factor (HGF), vascular endothelial growth factor (VEGF), stromal cell-derived factor-1 
(SDF-1/CXCL12), CXCL14, matrix metalloproteinases (MMPs) and the TGF-β 
family. These factors act as proliferative and morphogenic stimuli for the tumor and 
may also affect other properties such as angiogenesis, inflammation and remodeling of 
the ECM releasing for example sequestered growth factors (Augsten et al., 2009; 
Bhowmick and Moses, 2005; Bhowmick et al., 2004b; Orimo and Weinberg, 2006; 
Thijssen et al., 2004; Xing et al., 2010). Early experiments using human derived 
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fibroblasts overexpressing HGF together with human mammary epithelial cells 
transplanted into cleared fat pads of mice yielded invasive carcinomas, whereas 
fibroblasts not expressing HGF failed to induce carcinoma (Kuperwasser et al., 2004). 
HGF has mitogenic effects through signaling via its receptor cMet, commonly found on 
epithelial cells, in addition to migratory and angiogenic effects (Jiang et al., 2005). 
Another set of experiments investigated the molecular mechanism in more detail. 
Human CAFs enhanced tumor growth in mice when co-injected with breast carcinoma 
cells compared to normal human fibroblasts from breast. This was shown to be due to 
CAF derived SDF-1 which recruited endothelial progenitor cells enhancing 
angiogenesis but SDF-1 also have a direct effect on tumor cell proliferation (Orimo et 
al., 2005). CAFs produce several matrix-remodeling proteins, such as MMPs, and have 
in an in vitro model been shown to be able to lead the invasion of carcinoma cells that 
lack ability to remodel matrix themselves (Gaggioli et al., 2007).  
 
Gene expression profiling studies indicate a high degree of heterogeneity within the 
CAF population. Some of the differences are likely explained by the use of tumors of 
various origin, different methods and also the use of different criteria in defining the 
normal fibroblastic compartment used for comparison (Micke and Ostman, 2005). For 
example, the normal fibroblasts that the CAFs gene expression profile is compared to 
may be derived from the same patient at a certain distance from the tumor (Micke et al., 
2005) or from unrelated normal tissue (Allinen et al., 2004; Fukushima et al., 2004). 
The method of separating the CAFs from the tumor cells is also different, some used 
laser microdissection (Fukushima et al., 2004; Micke et al., 2005) whereas others chose 
antibody bead based cell sorting (Allinen et al., 2004). 
 
Orimo and colleagues have provided important information regarding the development 
of the phenotype of CAF isolated from breast carcinomas. The isolated CAFs, although 
heterogeneous, all stimulated tumor growth when co-injected with breast tumor cells 
subcutaneously compared to normal fibroblasts isolated from a healthy patient. 
Interestingly, fibroblasts isolated 2 cm away from the tumor also displayed similar 
changes as the isolated CAFs, albeit at considerably lower levels. The CAF co-injected 
tumors displayed increased angiogenesis due to increased expression of SDF-1 (Orimo 
et al., 2005). In a subsequent study, autocrine SDF-1 and TGF-β were identified as 
mediators of maintenance of the CAF phenotype (Kojima et al., 2010). 
 
1.2.1.3 Therapeutic implications of CAFs   
 
The CAFs in tumors poses an interesting opportunity for targeted therapies. PDGF 
inhibitors are already used in the clinic, although usually for other implications that is 
discussed below. One of the earliest targeted therapies directed towards CAFs was 
MMP inhibitors. They have been non-successful so far in clinical trails and display 
significant side effects (Bissett et al., 2005; Leighl et al., 2005; Miller et al., 2004; 
Rosenbaum et al., 2005). Considering that the attention that CAFs has been given in 
research is far less than that for angiogenesis, it is not surprising that not more targeted 
therapies are available. However with the increasing attention and knowledge the field 
is attracting, most likely novel therapies will be developed.   
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PDGFRs are commonly found in the tumor stroma. Tyrosine kinase inhibitors applied 
in a cervical cancer model and a colon cancer, where CAFs have been shown to express 
PDGFRs, significantly reduced tumor growth rate (Kitadai et al., 2006; Pietras et al., 
2008). Although suggestive of that this is part of the clinical effect of tyrosine kinase 
inhibitors in clinical trials, however, the evidence from the human situation is lacking. 
A recent publication suggests that targeting fibroblasts expressing FAP using a DNA 
vaccine strategy changed the immune response in the tumor and also sensitized them to 
chemotherapy (Liao et al., 2009). Another recent publication suggests targeting of 
paracrine hedgehog (Hh) signaling to the stroma by neutralizing antibodies or small 
molecule inhibitors. In short, Hh ligands were identified in a subset of human cancers. 
However, no activity of Hh signaling could be identified in human cancer cell lines but 
Hh inhibitors reduced tumor growth rate in vivo. Through co-injection experiments 
using MEFs deficient in Hh signaling they show that these fibroblasts recapitulate the 
growth inhibitory phenotype suggesting that they are the target of the Hh inhibitors in 
vivo (Yauch et al., 2008).    
 
A gene signature that predicts clinical outcome was identified using laser micro-
dissection of human breast cancer stroma (Finak et al., 2008). In another study, using a 
different approach where the stroma signature was extracted from the gene expression 
profile of tumor tissue, they were not able to predict clinical outcome, but instead 
identified patients less likely to benefit from neo-adjuvant therapy (Farmer et al., 2009).  
The major stromal component in breast tumors is CAFs, indicating that these results 
most likely reflect the CAF population in the tumors. 
 
1.2.2 The PDGF system  
The PDGFs are a family of four gene products forming five isoforms of dimeric 
disulphide bonded growth factors (Fredriksson et al., 2004a). They signal through two 
different tyrosine kinase receptors i.e. the PDGFR-α and PDGFR-β which homo- or 
heterodimerize to cross-phosphorylate each other	   (Claesson-­‐Welsh	   et	   al.,	   1989;	  Yarden	  et	  al.,	  1986).	  The	  PDGFR-­‐α interacts with all isoforms except PDGF-DD while 
PDGFR-β only binds to PDGF-B and -D chains with high affinity. PDGF-AB, -BB and 
-CC interacts with the PDGFR-αβ heterodimer	   (Fredriksson	   et	   al.,	   2004b).	  	  
Conflicting results have been reported with	   regard	   to	   the	   PDGF-­‐DD	   activation	   of	  
PDGFR-αβ heteromere	  (Bergsten	  et	  al.,	  2001;	  LaRochelle	  et	  al.,	  2001). The PDGFR 
signaling activates several intracellular downstream signaling pathways in a cell type 
specific manner (Rosenkranz and Kazlauskas, 1999).	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Figure 2. The structure of the PDGFR dimers and binding pattern of the different 
PDGF ligands to the receptors.  	  	  
The classical PDGFs, PDGF-AA, -AB and -BB, are secreted as activated proteins 
(Ostman et al., 1992) whereas the novel PDGFs, PDGF-CC and -DD need to be 
proteolytically activated	   (Bergsten	   et	   al.,	   2001;	   LaRochelle	   et	   al.,	   2001;	   Li	   et	   al.,	  2000b). Tissue plasminogen activator and urokinase-type plasminogen activator have 
been identified as the probable proteolytic enzymes for PDGF-CC and -DD 
respectively	  (Fredriksson	  et	  al.,	  2004b;	  Ustach	  and	  Kim,	  2005). Recently, matriptase 
was described as a new protease able to activate PDGF-CC (Hurst Jr et al., 2011). In 
addition, both PDGF-CC and -DD can be activated by plasmin, but due to the wide 
substrate specificity it is most likely not the physiologically relevant enzyme 
(Fredriksson et al., 2004b).	  
 
1.2.2.1 Functions of PDGFs 
 
The PDGFs have been shown to be important during development but there is limited 
information about their normal physiological functions in the adult situation (Andrae et 
al., 2008). Genetic studies in mice have revealed important information regarding the 
function of members of the PDGF signaling system during development. Knockout 
mice of pdgf-b, pdgfr-α and pdgfr-β are all embryonically lethal (Leveen et al., 1994; 
Soriano, 1994; Soriano, 1997). The pdgf-a knockout is lethal but time of lethality 
ranges from embryonic stage to 60 days postnatal, most likely depending on strain 
background (Bostrom et al., 1996). The pdgf-c knockout is viable, at least in some 
backgrounds (Ding et al., 2004). The pdgf-d knockout is yet to be reported. In short, the 
combination of pdgf-a and pdgf-b does not fully recapitulate the phenotype of pdgfr-α 
knockdown, suggesting that pdgf-c also contributes to embryonic development 
(Betsholtz et al., 2001; Ding et al., 2004). These knockouts display cleft palate, spina 
bifida and skin, lung and brain abnormalities with varying overlap (Andrae et al., 2008; 
Betsholtz, 2004). The pdgf-b and pdgfr-β kockouts are very similar. They develop 
A B B BA A C C D D
PDGF	  ligands
PDGF	  receptors
_ _ _ ` ` `
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cardiovascular complications and histological findings include several vascular 
abnormalities most likely due to inability to recruit mural cells (Betsholtz et al., 2001; 
Lindahl et al., 1997; Soriano, 1994). 
 
The PDGFs are involved in several pathological conditions including cancer, vascular 
diseases and fibrosis (Andrae et al., 2008). This is in line with the early notion that the 
PDGFs are a major mitogen for cells of mesenchymal origin, including vessel mural 
cells and fibroblasts (Heldin and Westermark, 1999).	  
 
1.2.2.2 PDGF-CC 
 
PDGF-CC expression has been demonstrated to induce fibrosis in a number of different 
organs such as liver, kidney and heart (Campbell et al., 2005; Eitner et al., 2008; Ponten 
et al., 2003). The phenotype of knock out of pdgf-c in mice has shown that PDGF-CC 
is important for palate formation, renal cortex formation and the lung, skeletal and 
vascular development. Spina bifida is also seen in the knockouts (Ding et al., 2004). 
Depending on the mouse background, the phenotype is more or less severe. C57Bl/6 
pdgf-c knockout mice are viable but numbers of surviving pups are slightly reduced 
compared to the expected Mendelian ratio. PDGF-CC has also been suggested to 
stimulate angiogenesis in different systems (Cao et al., 2002; Li et al., 2005) and in 
addition be implicated in regulation of the blood brain barrier integrity (Su et al., 2008).  
 
1.2.2.3 PDGFs in the tumor microenvironment 
 
All PDGF isoforms have been shown, in different carcinomas, to be produced by tumor 
cells. It is also common that the tumor cells lack expression of the PDGFR implying 
that the PDGFs produced in the tumor communicate with stromal cells and aid in their 
recruitment (Heldin and Westermark, 1999; Micke and Ostman, 2005). Autocrine 
stimulation or activating mutations of PDGFRs of tumor cells has been described 
(Ostman, 2004) but will not be discussed further here.  
 
Early research performed has focused on the outcome effect of tumor cell PDGF-BB 
expression in melanoma on the tumor stromal compartment in tumor initiation and 
development. These experiments suggested that tumor microenvironment stimulated 
with PDGF-BB was able to increase stroma formation and angiogenesis (Forsberg et 
al., 1993). Similar results were obtained when PDGF-BB was expressed in non-
tumorigenic keratinocytes. This resulted in induction of an activated stroma and 
angiogenesis and promoted the keratinocyte conversion into tumorigenic cells (Skobe 
and Fusenig, 1998). In line with this, Shao and colleagues show that breast cancer cells 
expressing the classical PDGFs are able to induce a desmoplastic response when 
injected orthotopically (Shao et al., 2000). Additional information regarding the effect 
of PDGF-BB and -DD expression was obtained in the B16 melanoma mouse model 
where these factors increased the pericyte abundance in tumors conferring an increased 
tumor growth rate (Furuhashi et al., 2004). Giving mechanistic insight into the tumor 
angiogenesis induced by PDGFs, PDGFR-α signaling was demonstrated to be required 
for recruitment of host fibroblast secreting VEGF in a fibrosarcoma system devoid of 
tumor VEGF expression (Dong et al., 2004).  
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The interstitial fluid pressure (IFP) is elevated in most solid tumors. This occurs due to 
abnormal vascular and interstitial permeability and capillary pressure. IFP is an 
important factor for efficient drug delivery into tumors and distribution within tumors 
as the high IFP may require elevated blood concentration of drugs to achieve the 
correct dose for the tumor, hence, increasing the toxicity to the rest of the body (Lunt et 
al., 2008). Inhibition of the PDGFRs results in increased drug delivery to the tumor in 
several tumor models (Pietras et al., 2001; Pietras et al., 2002; Pietras et al., 2003). 
 
Recently, several studies investigating the significance of PDGFR expression in human 
cancers have been published. Interestingly, using the PDGFRs as markers, they identify 
four different subsets of CAFs expressing none, one receptor or both receptors in 
several different cancers. High stromal fibroblast expression of PDGFR-β in human 
breast cancer samples was associated with a shorter recurrence free survival and shorter 
breast cancer specific survival, hence high PDGFR-β expression in fibroblasts display 
prognostic significance (Paulsson et al., 2009).  Stromal PDGFR-β expression in 
prostate cancer has also been shown to correlate with several characteristics of poor 
prognosis (Hagglof et al., 2010). A subset of glioblastoma tumors display tumor cell 
PDGFR-α expression and amplification of the pdgf-a gene. Histopathological 
investigation of PDGFR and activated PDGFR status of tumors from patients 
participating in a trial, where the tyrosine kinase inhibitor imatinib was used together 
with chemotherapy, revealed that activated PDGFR-α in tumor cells was associated 
with reduced survival. However, the addition of imatinib to chemotherapy did not 
improve survival (Paulsson et al., 2011).  
 
1.2.2.4 PDGF-CC in the tumor microenvironment 
 
In 2001 pdgf-c was suggested to be an important mediator of malignancy in the Ewing 
family tumors (Zwerner and May, 2001).  As previously mentioned, PDGF-CC 
overexpression in liver induces liver fibrosis causing multifocal liver tumors in mice 
(Campbell et al., 2005). Investigating the phenotype closely revealed an increased 
proliferation of both hepatic stellate cells and endothelial cells preceding the tumor 
development in these mice. As imatinib treatment was able to block stromal cell 
proliferation in this model they suggest this as a possible treatment for human 
hepatocellular carcinoma with expression of c-kit or PDGFRs (Campbell et al., 2007). 
PDGFR-α signaling has been shown to be involved in recruiting stromal fibroblasts 
into lung tumors in a mouse model. However, both PDGF-AA and -CC is present in 
this system. In addition, the two ligands are present in human lung tumors along with 
expression of PDGFR-α (Tejada et al., 2006). Further insight into the role of stromal 
PDGF signaling in tumor development was provided in a genetically engineered mouse 
model of cervical cancer. The PDGFRs are expressed in the stromal compartment. 
Inhibiting tyrosine kinases through imatinib treatment reduces tumor growth through 
actions on angiogenesis by reducing FGF-2 production by CAFs. The ligand most 
abundantly expressed was pdgf-c and high PDGF-CC expression was also noted in 
human tumor epithelium suggesting that it is the responsible ligand for the observed 
phenotype (Pietras et al., 2008). CAFs isolated from VEGF treatment responding or 
resistant tumors reveal that PDGF-CC was expressed by the resistant CAFs and that 
neutralizing PDGF-CC using antibodies attenuated the sustained angiogenesis provided 
by the CAFs in the resistant tumors (Crawford et al., 2009).  PDGF-CC expression has 
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also been noted in glioblastoma. Overexpression of PDGF-CC in glioblastoma cells 
resulted in tumors displaying a normalized vasculature with reduced permeability and 
vessel diameter together with an increase in pericyte coverage. The use of a VEGF 
antibody in the PDGF-CC overexpressing tumors had no effect while the therapy has 
effect in the parental tumor (di Tomaso et al., 2009). Taken together, these 
experimental results suggest that targeting either the PDGF ligand or receptor may be a 
successful strategy when these targets are expressed in the human situation. 
 
1.3 ANGIOGENESIS  
Angiogenesis is the formation of blood vessels from existing blood vessels, as opposed 
to vasculogenisis where the vessels are formed de novo. The blood vessels are built up 
by endothelial cells, which are surrounded by BM and mural cells, pericytes or vascular 
smooth muscle cells. The vascular system is normally quiescent in the adult except for 
wound healing and during the female reproductive cycle. New studies also suggest that 
the endothelium have important functions in determining size and regeneration of 
organs. Through pneumonectomy and hepatectomy experiments in mouse models it has 
been shown that endothelial derived cues directs epithelial regeneration (Ding et al., 
2010; Ding et al., 2011). Angiogenesis is kept quiescent through a delicate balance of 
pro- and antiangiogenic factors. A number of factors have been implicated in 
angiogenesis. Important signaling systems include VEGF, FGF, Notch signaling, 
angiopoietins, PDGF and TGF-β which all have been shown to have important 
functions during vascular development in mouse and zebra fish model systems 
(Betsholtz, 2004; Bikfalvi et al., 1997; Ferrara, 2004; Gale and Yancopoulos, 1999; 
Gridley, 2010; ten Dijke and Arthur, 2007). 
 
1.3.1 Tumor angiogenesis 
It is now almost exactly 40 years ago since Folkman published his now famous review 
articulating old hypotheses that inhibiting angiogenesis in tumors would be a good 
treatment to inhibit tumor growth (Folkman, 1971). In order for the tumor to grow 
beyond a few millimeters in size it needs to secure its blood supply. Interference with 
the intricate balance of angiogenic effector molecules early during the tumorigenic 
process is imperative to turn on the angiogenic switch and tip the balance in favour of 
angiogenesis and hence, sustained tumor growth (Hanahan et al., 1996; Hanahan and 
Folkman, 1996). Prototypical angiogenic inducers in tumors include VEGF and FGF 
growth factors (Hanahan and Folkman, 1996). The vessels in the tumor are commonly 
tortuous and display abnormal features with regard to permeability, morphology and 
composition (Baluk et al., 2005; Bergers and Benjamin, 2003; Hashizume et al., 2000; 
Hillen and Griffioen, 2007; Jain, 2003). 
 
1.3.1.1 Antiangiogenic therapy 
 
Antiangiogenic therapy has been very successful in preclinical experiments. One of the 
first experiments showing that inhibition of antiangiogenic factors reduced tumor 
growth rate and vessel density was reported in 1993. They treated three different 
subcutaneously growing tumors with VEGF inhibitory antibodies (Kim et al., 1993). 
Inhibiting angiogenesis using endostatin instead in three syngeneic tumor mouse 
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models, it was suggested that angiogeneisis inhibitors were not able to induce 
resistance as treatment was discontinued once the tumor had regressed and re-initiated 
when the tumor regrew. This was repeated in several cycles until the tumors did not 
regrow (Boehm et al., 1997).  The efficacy of VEGF kinase inhibitors on tumor growth 
rates in subcutaneous models was reported later (Fong et al., 1999; Wood et al., 2000).  
 
There were high hopes when antiangiogenic therapy was introduced into the clinic in 
the form of the VEGF monoclonal antibody bevacizumab (Avastin) 2004 (Folkman, 
2006).  However, the high hopes were not fulfilled with regard to overall survival and a 
limited effect of a few moths increase in progression free survival in renal cell 
carcinoma and metastatic colon cancer (Escudier et al., 2007; Hurwitz et al., 2004; 
Motzer et al., 2007). Earlier this year, the United States Food and Drug Administration 
revoked the approval for use of bevacizumab in breast cancer due to lack of increased 
overall survival (Twombly, 2011). Evasive resistance most likely brings on the lack of 
increase in overall survival.  
 
Thorough investigations in preclinical mouse models have implicated several 
mechanisms of resistance, either inherent or acquired, that may be the explanations to 
the absent clinical survival benefit to the antiangiogenic treatments (Bergers and 
Hanahan, 2008; Ebos et al., 2009b). In more detail, glioblastoma tumors have shown a 
pattern of slowed down tumor growth and reduced vascularity when treated with anti-
VEGF antibodies, but the tumor invasive pattern changed and the tumor co-opted 
normal host vessels (Rubenstein et al., 2000). Induction of other pro-angiogenic factors 
have also been noted when tumors adapt and acquire resistance to anti-VEGF therapy. 
Tumor growth was retarded transiently but after a short period the tumors again 
appeared at equal size. The mechanism behind this induced resistance was hypoxia-
induced induction of FGF-2 and other proangiogenic factors (Casanovas et al., 2005). 
 
It is known that pericytes are able to stabilize vessels and that targeting both pericytes 
and endothelial cells simultaneously is beneficial (Bergers et al., 2003). VEGF therapy 
has also been shown to increase pericyte coverage of vessels, protecting the vessels for 
the effect of the antiangiogenic treatment (Bergers et al., 2003; Jain, 2005; Jain and 
Booth, 2003; Pietras and Hanahan, 2005). In addition, pericyte marker expression 
changes upon anti VEGF therapy suggestive of induction of changes in the pericytes 
upon antiangiogenic therapy (Franco et al., 2011a). A study of melanoma in a mouse 
model showed that some tumors are inherently resistant to antiangiogenic therapy with 
VEGF inhibitors due to a different vessel structure and high degree of pericyte 
coverage (Helfrich et al., 2010). Recently, detailed studies have described that 
pericytes, through integrins, induce a survival signal in endothelial cells involving 
VEGF and the antiapoptotic factor Bcl-w (Franco et al., 2011b). Another mechanism to 
restore angiogenesis that has been described is recruitment of BMDC as a result of 
hypoxia in the tumor (Bergers and Hanahan, 2008).  Other cell types, inflammatory 
cells and CAFs, in the tumor microenvironment can also aid the tumor to overcome 
anti-VEGF therapy by expression of angiogenic factors (Crawford and Ferrara, 2009; 
Crawford et al., 2009; Shojaei et al., 2007).  
 
Metastases are a major problem in the clinic and are responsible for about 90% of the 
cancer related deaths (Steeg and Theodorescu, 2008).  Recent reports have highlighted 
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the connection between antiangiogenic therapy and enhancement of metastasis. 
Specifically, both genetic and therapeutic targeting of the VEGF pathway caused 
tumors displaying enhanced invasion and increased metastasis (Paez-Ribes et al., 
2009). In addition, a small molecule kinase inhibitor targeting the VEGF/PDGF 
receptors caused accelerated metastasis in parallel to an antitumoral effect on a bulk 
tumor (Ebos et al., 2009a). However, so far there are no reports from the clinic 
regarding the enhancement of metastasis following resistance to antiangiogenic 
therapy.  
 
1.3.2 The TGF-β family 
TGF-β signaling is portrayed as a dual player during tumorigenesis with generally a 
tumor suppressive role in the premalignant state and a tumor promoting effect at later 
stages (Massague, 2008; Tian and Schiemann, 2009). The TGF-β paradox has been 
investigated for years but we still have a lot to learn about this complex and intricate 
signaling system.  
 
 
 
Figure 3. Illustration of the TGF-β paradox. 
TGF-β signalling is involved in both tumor suppression and promotion activities.  
 
 
The TGF-β family has a large number of ligands divided into subclasses comprising of 
TGF-βs, Activins, Nodal, BMPs, growth and differentiation factors, and muellerian 
inhibiting substance (Shi and Massague, 2003). The ligands act as dimers signaling 
through serine/threonine kinase receptors of two different classes, TGF-β type I and 
type II receptors with seven and five members respectively. There are also three co-
receptors sometimes referred to as type III receptors. The dimeric ligand binds to 
dimers of type II and type I receptors forming a heterotetrameric comlex, sometimes 
including type III receptors in the large signaling complex. The exact order of events 
varies (Schmierer and Hill, 2007). The type I receptor is phosphorylated by the type II 
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receptor which causes recruitment of the receptor-regulated SMADs. The type I 
receptor phosphorylates the receptor-regulated SMAD which then forms a heteromeric 
complex together with SMAD4. This complex is translocated to the nucleus where it 
participates in regulation of target genes. Inhibitory SMADs are induced by SMAD 
signaling and mediate negative feedback on TGF-β signaling (Moustakas and Heldin, 
2005). This canonical intracellular signaling pathway has been conserved throughout 
evolution. In addition there are also other, non-SMAD signaling pathways identified. 
Cytoplasmic effector molecules that have been identified include Ras, mitogen-
activated protein kinases, extracellular-signal-regulated kinases, p38 and c-Jun N-
terminal kinases. Most of these downstream signaling proteins were identified in vitro 
by pharmacological inhibitors and the exact link and order of events remains to be 
identified (Moustakas and Heldin, 2005). 
 
The members of the TGF-β family are important for a number of processes during 
development, in the adult and in several diseases. The discussion here will focus on 
the role of the TGF-β family in cancer. The TGF-β family has the ability to impinge 
upon tumor cells and all cell types in the tumor microenvironment (Tian and 
Schiemann, 2009). In the premalignant state, TGF-β inhibits malignancy through 
regulation of proliferation, differentiation, survival, adhesion, cytokine and ECM 
production. TGF-β singling in epithelial cells blocks transcription of c-myc, which is 
important for growth inhibition (Moses et al., 1991). The tumor cells circumvent the 
inhibitory action for example through inactivation of core components, such as 
mutations of the type II TGF-β receptor, TβRII, or SMAD4, of the signaling pathway 
regulating the specific trait turning it into a tumor promoting property. However, 
when these are mutated in mice it is not sufficient for tumor formation and another 
stimulus such as tissue injury for example, which change the environment inducing 
proliferative cues, is needed (Massague, 2008; Tian and Schiemann, 2009). This can 
be exemplified by a study where the TβRII was mutated in mammary epithelia. The 
mere deletion induced hyperplasia and increased apoptosis but when combined with 
the MMTV-PyMT mouse model tumors were detected earlier and metastasis was 
enhanced (Forrester et al., 2005). Endothelial cells may respond with proliferation, 
migration and morphogenesis upon TGF-β stimuli or the opposite but this will be 
discussed in more details later (Goumans et al., 2003a). Fibroblasts are also important 
targets for TGF-β signaling in tumors where signaling affects ECM production, 
proliferation and cytokine secretion. As opposed to TβRII inactivation in epithelial 
cells not being enough for malignant transformation, TβRII deletion in FSP-1 
expressing fibroblasts induced squamous cell carcinoma in the forestomach through 
upregulation of HGF (Bhowmick et al., 2004a). TGF-β is also a major player in EMT 
and EndMT and has effects on the immune system as it is a key component in the 
induction of immune tolerance (Massague, 2008; Tian and Schiemann, 2009). The 
implications of TGF-β signaling in cells other than endothelial cells will not be 
discussed further. In summary, the TGF-β signaling and effects are highly complex 
and the outcome of manipulating the system may yield unexpected and difficult to 
interpret results. With the use of the new and complex mouse models we are starting 
to understand more about this intriguing system and the deciphering will continue.   
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Figure. 4. TGF-β effects on different cell types. 
TGF-β exerts a number of diverse effects in a context dependent manner on many cell 
types, reflecting its dual role in tumor biology. 
 	  
1.3.2.1 Endoglin 
 
Endoglin (also CD105) is a type III TGF-β co-receptor. It is highly expressed in 
endothelial cells during active angiogenesis whereas it is expressed at low or non-
detectable levels in non-active endothelial cells (Burrows et al., 1995; Fonsatti et al., 
2000; Miller et al., 1999). Endoglin is considered as an endothelial cell marker but is 
expressed on some other cell types, mostly under certain specific conditions such as 
on monocytes during monocyte-macrophage transition, syncytiotrophoblasts in the 
placenta at term, a subset of neural crest stem cells during development, adult bone 
marrow hematopoetic stem cells and mesenchymal stem cells (Schieker et al., 2007; 
ten Dijke et al., 2008). The receptor has a large extracellular domain and a short 
cytoplasmic domain. There are two isoforms, long- and short-endoglin with the 
length of the cytoplasmic tail deviating. The long form is the preferentially expressed 
variant, particularly in the endothelium (Perez-Gomez et al., 2010). Endoglin is also 
present in a soluble form and MMP-14 was recently shown to be responsible for 
producing soluble endoglin from the membrane bound form (Hawinkels et al., 2010). 
Out of the large TGF-β family ligands, endoglin binds to TGF-β1, TGF-β3, activin-
A, BMP-2, BMP-7, BMP-9 and BMP-10. However, BMP-9 and BMP10 are the only 
ligands that membrane bound endoglin can bind to without the presence of the TGF-β 
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type I and type II receptors (Barbara et al., 1999; Bellon et al., 1993; Castonguay et 
al., 2011; Cheifetz et al., 1992; Letamendia et al., 1998; Scharpfenecker et al., 2007). 
 
When endoglin expression is ablated in mice challenged with tumors, these tumors 
have displayed a reduced growth rate as a result of lower vascular density (Duwel et al., 
2007). Tumor models where endoglin function is inhibited using antibodies or vaccine 
strategies have displayed similar phenotypes with reduced tumor growth and lower 
vascular density, sometimes in combination with diminished metastasis (Seon et al., 
1997; Takahashi et al., 2001a; Tan et al., 2004; Uneda et al., 2009). Endoglin is 
commonly up-regulated in the tumor vessels in several different tumor types and has 
been shown to have prognostic significance (Burrows et al., 1995; Charpin et al., 2004; 
Kumar et al., 1999; Martone et al., 2005; Wikstrom et al., 2002). Soluble endoglin 
seems to act as an inhibitor of endoglin effects (Castonguay et al., 2011; Hawinkels et 
al., 2010) (Hawinkels 2010, Castonguay et al, JBC 2011) and high levels of circulating 
endoglin have been reported to correlate to occurrence of metastasis in breast and colon 
carcinoma (Takahashi et al., 2001b).  Endoglin inhibitors are under investigation and 
the human chimeric antibody TRC105 (Matsuno et al., 1999) has entered clinical trials. 
 
1.3.2.2 ALK1  
 
ALK1 is a TGF-β type I receptor with expression restricted to the endothelium. The 
ligands of ALK1 were unknown for quite some time but to date BMP9, BMP10, TGF-
β1 and TGF-β3 have been shown to interact with ALK1 under some conditions (David 
et al., 2007; Goumans et al., 2003b; Goumans et al., 2002; Suzuki et al., 2010). It is 
however debated which is the true ALK1 ligand (David et al., 2009). Activation of 
ALK1 induces phosphorylation of receptor-regulated SMAD1/5/8 as opposed to 
receptor-regulated SMAD2/3 which is induced by ALK5 signaling (van Meeteren and 
Ten Dijke, 2011). 
 
It is to date not fully elucidated how ALK1 modulates angiogenesis. There are many 
contradictory reports and several levels of complexity. Despite this, several means of 
inhibiting ALK1 signaling, both through kinase inhibitors and soluble receptor 
analogues, are currently under investigation (Cunha and Pietras, 2011). 	  
 
1.3.2.3 TGF-β family signaling in the endothelium 
 
TGF-β signaling is highly dependent on context and cellular differentiation stage. The 
complex results of TGF-β signaling in the vessels have not been thoroughly 
investigated and it is also common with contradictory results. Part of the explanation to 
the many contradictory results obtained is that many studies have been performed in 
vitro with emphasis on one ligand and/or receptor family member not taking into 
account the complexity in the in vivo situation where multiple ligands and multiple 
receptors may be present in a number of different combinations. However, the in vitro 
studies are also very important in order to study the complex effects of TGF-β signaling 
but should be designed with great attention on details, such as ligand availability of the 
specific site in vivo. We are still lacking many very important pieces of information to 
explain the TGF-β family’s intricate, diverse and contradictory effects in angiogenesis. 
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Figure 5. Schematic illustration of the TGF-β signalling components in the 
endothelium. 
Endothelial cells have been shown to express a number of different TGF-β receptors. 
Expression of three different type I receptors, ALK1, ALK2 and ALK5, three type II 
receptors, TβRII, BMRII and ActRII in addition to two type III receptors, endoglin and 
betaglycan have been reported. 
 
Endothelial cells express two different TGF-β type I receptors, the ubiquitously 
expressed ALK5 and the endothelial restricted ALK1. Endothelial cells may also 
express ALK2 and the co-receptors endoglin and betaglycan (David et al., 2009; David 
et al., 2007; van Meeteren and Ten Dijke, 2011). Deletion experiments in mice have 
shown a high degree of similarity between phenotypes when ALK1, ALK5, Endoglin 
and TβRII are knocked out. They are all embryonically lethal around mid gestation due 
to vascular defects (ten Dijke and Arthur, 2007).  This suggests that they all have 
important functions that are non-redundant in the developing embryo, which also may 
translate into important functions during tumor angiogenesis. Interestingly, functional 
mutations resulting in a heterozygote phenotype of endoglin or ALK1 are found in the 
human disease hereditary haemorrhagic telangiectasia (HHT). The phenotype is 
slightly different between the variants but is characterized by arteriovenous 
malformations and telangiectasia induced bleedings in the gut and nose (Shovlin, 
2010).  
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TGF-β1 binds both to the ALK1 and ALK5 receptor in the endothelial cell. It has been 
proposed that these two receptors have opposite effects on angiogenesis directing 
signaling either towards pro-angiogenesis with migration and proliferation or a 
quiescent state, respectively. To dissect this constitutively active ALK1 or ALK5 
receptors were expressed in endothelial cells and subject to microarray analysis 
revealed some specific target genes for each receptor, plasminogen activator inhibitor 
type 1 (PAI-1) and fibronectin for ALK5 and inhibitor of DNA binding (ID)1 and 
interleukin 1 receptor like 1 (IL1RL1) for ALK1 (Goumans et al., 2002). Interestingly, 
PAI-1 is an inhibitor of angiogenesis in vivo (Stefansson et al., 2001) and ID1 has been 
shown to enhance migration, invasion and proliferation in endothelial cells while 
IL1RL1 is suggested to be involved in cell growth (Goumans et al., 2003a; Goumans et 
al., 2002; Lin et al., 2000). They suggest that ALK1 has growth stimulatory effects on 
endothelial cells. However, another study showed that the constitutively active ALK1 
inhibited cell cycle progression suggested that ALK1 is important for the maturation 
stage of vessel formation (Lamouille et al., 2002). The two studies also reported 
conflicting results regarding c-myc expression. The constitutively active ALK5 
rendered endothelial cells with reduced migration and proliferation, which they 
implicate in vessel maturation (Goumans et al., 2002). Explanations for the discrepancy 
of the results may be the use of different cell lines and also culturing conditions. The 
role of endoglin in this signaling complex has been described as modulating the 
signaling in favour of ALK1 and inhibiting ALK5 (Goumans et al., 2002). Knockdown 
of endoglin in endothelial cells caused suppression of growth and migration indicating 
that endoglin presence is important for angiogenesis (Li et al., 2000a).  Adding strength 
to the suggested balance where ALK1 and endoglin enhance while ALK5 suppresses 
angiogenesis is the similarities seen between knockdown of endoglin and ALK1 in 
vivo. The knockouts display very similar phenotypes and the corresponding human 
diseases, HHT1 and HHT2 respectively, also display overlapping symptoms. Efficient 
signaling by ALK1 has also been shown to require the presence of ALK5 in cultured 
endothelial cells. Endothelial cells lacking ALK5 failed to respond to TGF-β 
stimulation even in the presence of ALK1 or overexpressed ALK1 (Goumans et al., 
2003b). These results were not supported by another study where endothelial 
conditional knockout mice of ALK1, ALK5 and TβRII were compared. The ALK1 
deletion exhibited vascular malformations while the conditional knockouts did not 
indicating that ALK1 is not dependent on ALK5 presence (Park et al., 2008). 
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2 AIMS 
	  
 
The tumor’s stroma, composed of many different cell types, contain many, yet 
unidentified, signaling pathways and processes that we conceive are promising new 
druggable targets. The tumor micro- and macroenvironment are highly plastic 
compartments with the ability to adapt to the insults of treatment. By simultaneously 
targeting multiple signaling pathways and cell types, we believe that cancer can be 
treated more efficiently than today with perhaps less side effects.  
 
To achieve this, we have to improve our current understanding of the complex and 
intricate molecular interactions that governs paracrine signaling in the tumor 
microenvironment. Specifically, molecular interactions and paracrine signaling by 
CAFs and endothelial cells will be explored in vivo. We aim to investigate the 
dependence of these cell types on signaling through members of the PDGF family and 
the TGF-β family respectively. 
 
 
Specific aims: 
 
• To investigate the effect of paracrine PDGF-CC signaling on the tumor 
microenvironment (Paper I). 
 
• To investigate the significance of PDGF-CC expression in breast cancer and 
explore the therapeutic opportunities of monoclonal PDGF-C antibodies (Paper 
II). 
  
• To elucidate the function of TGF-β signaling in the tumor microenvironment, 
focusing on the effects of ablated TGF-β signaling via the endothelial receptors 
endoglin (Paper III) and ALK1 (Paper IV). 
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3 RESULTS AND DISCUSSION 
	  
3.1 PAPER I: PARACRINE SIGNALING BY PLATELET-DERIVED 
GROWTH FACTOR-CC PROMOTES TUMOR GROWTH BY 
RECRUITMENT OF CANCER-ASSOCIATED FIBROBLASTS.  
Several studies have implicated PDGFs as prominent factors creating a growth 
promoting tumor stroma. Most studies have focused on the classical PDGFs and 
especially PDGF-BB. Tumors expressing PDGF-BB display a reduced latency time 
and present with increased number of vessels and fibrosis (Forsberg et al., 1993). In 
addition, paracrine PDGF-BB has been shown to create a growth permissive stroma for 
keratinocytes (Skobe and Fusenig, 1998). Later, stimulation of CAFs producing VEGF 
initially and later HGF was identified as the driving force for the creation of the 
permissive stroma (Lederle et al., 2006). PDGF-AA has been implicated in CAF 
recruitment to tumors as down regulation of pdgf-a in tumor cells reduced the 
desmoplastic response (Shao et al., 2000). In addition, another tumor model with 
abundant stroma was shown to express high levels of PDGF-AA. Inhibition of 
PDGFR-α reduced the tumor growth rate. Elevated pdgf-c gene expression was also 
noted but the relative contribution of PDGF-AA and PDGF-CC was not addressed 
(Tejada et al., 2006). However, there is no information regarding the mechanism 
whereby this occurs, where the cells are recruited from and the molecular functional 
consequences in the tumors. Thus, the classical PDGFs are important for the 
stimulation of the stromal compartment, creating a tumor permissive 
microenvironment.  
 
Less is known about the importance of paracrine signaling in tumors by the novel 
PDGFs. PDGF-CC has been shown to induce fibrosis in tissues such as liver, heart and 
kidney (Campbell et al., 2005; Eitner et al., 2008; Ponten et al., 2003). The expression 
of PDGF-CC is increased in several different skin cancers compared to the normal 
situation. Therefore, we wanted to study the effect of paracrine PDGF-CC signaling in 
a syngeneic tumor model.  
 
We started by confirming PDGF-CC expression and expression pattern of the receptor, 
PDGFR-α, in normal skin and malignant melanoma. Tumor cells in melanoma 
expressed PDGF-CC whereas PDGFR-α was present in cells of fibrotic streaks with 
fibroblast morphology. In normal skin, PDGF-CC expression was restricted to hair 
follicles and PDGFR-α expression was weak.  
 
We decided to express PDGF-CC in B16 melanoma cells, which are syngeneic to 
C57Bl/6 mice. These cells did not appear to be affected by the expression of PDGF-CC 
in vitro. However, when injected subcutaneously, they grew significantly faster. The 
tumors expressing PDGF-CC exhibited increased proliferation as shown by BrdU 
incorporation in combination with augmented vessel density. The apoptotic rate was 
reduced and there was no difference in pericyte coverage of vessels when assessed with 
the pericyte marker NG2.   
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We noted an increased thickness of the fibrous capsule surrounding B16/PDGFC 
tumors. This capsule contained PDGFR-α positive cells. To investigate this in more 
detail we established B16 PDGF-CC expressing and control tumors in PDGFR-α/GFP 
mice where one allele of PDGFR-α is substituted by GFP. This allowed us to identify a 
GFP positive population of cells infiltrating the tumor edge in PDGF-CC expressing 
tumors. The GFP positive cells were identified as fibroblasts by their expression of the 
fibroblastic marker FSP-1, which was present both at the tumor edge and in the tumor 
parenchyma. The abundant FSP-1 expression in the B16 tumors was dependent on 
activation of PDGFR-α as B16 tumors formed from cells expressing PDGF-BB was 
devoid of FSP-1 infiltrating cells.  
 
To identify the proteins that were responsible for the increased tumor growth rate in 
PDGF-CC expressing tumors we used antibody arrays allowing simultaneous 
assessment of 96 different proteins. OPN was highly expressed in the PDGF-CC 
tumors and in addition, FGF-2 expression was also increased. Cells of the fibrotic 
capsule and single infiltrating cells in the tumors were found to express OPN in 
immunohistochemical stainings.  
 
Three different subsets of CAFs were identified using FSP-1 staining in the tumors 
from PDGFR-α/GFP mice. At the tumor edge, cells expressing high PDGFR-α were 
present together with a second subset of PDGFR-α low expressing cells co-expressing 
FSP-1. In the center of the tumor, the third subset only expressing FSP-1 was 
identified. All these populations expressed α-SMA to various degrees. The 
combination of markers expressed identified these three populations of cells as CAFs. 
Co-stainings with OPN revealed that the predominant cells producing it were CAFs of 
the PDGFR-α low/FSP-1 subclass. However, some FSP-1 expressing cells also 
expressed OPN.  
 
The functional dependence of the B16 tumors on OPN was investigated using co-
injections of B16 cells and mouse embryonic fibroblasts (MEFs) derived from wild 
type or OPN deficient mice. Co-injection of tumor cells with wild type MEFs reduced 
the tumor latency time and increased the tumor growth rate while OPN deficient MEF 
tumors displayed latency time and tumor growth rate comparable to injection of tumor 
cells alone. Thus, identifying OPN as a functional important protein for melanoma 
growth.  
 
From these studies we concluded that PDGF-CC expression resulted in an increased 
recruitment of CAFs to the tumor. These CAFs expressed OPN, which induced an 
increased tumor growth rate. OPN is a ubiquitously expressed secreted protein. It is 
commonly expressed in tumors and associated with poor prognosis (Anborgh et al., 
2010). CAFs have in many different systems been implicated in angiogenesis, be it 
directly or indirectly, as they have been shown to secrete factors such as VEGF, 
CXCL14 and CXCL12/SDF-1 (Augsten et al., 2009; Fukumura et al., 1998; Orimo et 
al., 2005). OPN has been shown to induce angiogenesis and the effect was potentiated 
when FGF-2 was present (Leali et al., 2003). Interestingly these are the two 
differentially expressed proteins in our system when PDGF-CC recruits fibroblasts. 
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The angiogenic factor FGF-2 has been found to be important for tumor growth in a 
cervix cancer mouse model. FGF-2 expression was ablated when PDGF signaling was 
blocked using tyrosine kinase inhibitors (Pietras et al., 2008). In line with these results 
we also found that FGF-2 expression by CAFs increased in PDGF-CC expressing 
tumors. OPN has been shown to be important for recruiting bone marrow derived cells 
(BMDC), which induced a growth promoting stroma through activation of CAFs. 
These CAFs were not recruited from the bone marrow (Elkabets et al., 2011; 
McAllister et al., 2008). OPN is also found on the stromal gene list produced by Finak 
and colleagues that is associated with poor outcome in breast cancer (Finak et al., 
2008). 
   
We speculate that the three different CAF populations that we identified in the tumors 
may be the result of education of a cell type that expresses PDGFR-α. This could be 
resident fibroblast but intriguingly, MSC also express PDGFR-α (Ball et al., 2007). We 
hypothesise that PDGFR-α expressing cells are educated by the tumor 
microenvironment to evolve into CAFs expressing the effector proteins we identified in 
this study, OPN and FGF-2. Another option is that OPN itself is responsible for 
recruiting BMDC that in turn are responsible for the observed phenotype through an 
indirect mechanism.  
 
Another study has shown that CAFs expressing FSP-1 are able to induce metastasis 
through the effector molecules, VEGF and tenacin-C (O'Connell et al., 2011). It would 
be interesting to investigate whether metastasis is increased in our system as OPN has 
been implicated in induction of a growth promoting stroma at distant sites (McAllister 
et al., 2008). OPN expression has also been shown to be up-regulated in metastases of 
melanoma (Jaeger et al., 2007).  
 
We suggest that tumor growth will be reduced if PDGF-CC is targeted which 
presumably would reduce the content of OPN and FGF-2 in PDGF-CC expressing 
melanomas. PDGF-CC signaling can be targeted through use of tyrosine kinase 
inhibitors such as imatinib, sunitinib and sorafenib, which already are used in the clinic 
(Board and Jayson, 2005). Alternatively, OPN and FGF-2 could be targeted. These 
effects may not be restricted to melanoma alone, but would presumably display 
therapeutic potential in other tumors where PDGF-CC is present and involved in 
recruiting an activated stroma.  
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3.2 PAPER II: HIGH EPITHELIAL PDGF-CC EXPRESSION PREDICTS 
CLINICAL OUTCOME IN BREAST CANCER. 
We have previously identified PDGF-CC as an important growth factor for recruitment 
CAFs to melanoma in a mouse model. PDGF-CC was also found to be up-regulated in 
several human skin tumors of different types and the corresponding receptor PDGFR-α 
was found in the fibrotic streaks of malignant melanomas (Paper I).  During the 
initiation of this project PDGF-CC expression was assessed in ten different tumor 
types. Breast tumors displayed highly increased PDGF-CC expression compared to 
normal breast tissue.  
 
Apart from general clinical characteristics such as tumor grade, size and lymph node 
status the expression of hormone and growth factor receptors; estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) hold 
prognostic information and guide the use of targeted therapies in breast cancer 
(Gradishar, 2005). We set out to investigate whether PDGF-CC expression in breast 
cancer could be used as a prognostic marker and possibly pose as a target for therapy. 
 
First, a monoclonal PDGF-C antibody, clone 1, was developed. Clone 1 recognized 
human PDGF-CC, both latent and activated form, on western blot. It did not show 
immunoreactivity towards PDGF-DD. Clone 1 blocked ligand-induced 
phosphorylation of PDGFR-α in vitro and inhibited PDGF-CC stimulated cell growth.  
 
PDGF-CC expression was then characterized using clone 1 on tissue microarrays of a 
large (890 patients) patient cohort. The stromal and epithelial expression were scored 
separately as both stromal and epithelial cells expressed PDGF-CC. PDGF-CC 
expression increased during tumor progression and expression of PDGFR-α was 
confirmed in the stromal compartment in a selected subset of tumors. Epithelial PDGF-
CC expression was shown to be positively correlated with tumor grade, cytokeratin 5/6, 
HER2 and proliferation assessed by Ki-67 in Spearman rank analyses.  Negative 
correlations were found for ER, PR and menopausal status. Epithelial PDGF-CC 
expression displayed independent prognostic value for overall survival. Interestingly, 
PDGF-CC expression correlated with marker characteristics that have been assigned to 
basal-like breast cancer. As PDGF-CC expression correlated positively with epidermal 
growth factor receptor and cytokeratin5/6 and negatively with ER, PR and tumor grade 
this suggest that PDGF-CC may be a marker of basal like breast cancer. Basal-like 
breast cancer patients generally have an unfavourable prognosis with poor treatment 
response to traditional dosing schedules (Gluz et al., 2008). This also correlates with 
the poor prognosis of patients expressing epithelial PDGF-CC.   
 
We investigated the effects of PDGF-CC in an orthotropic breast tumor model. The 
human MDA-MB-231 cell line was shown to have high pdgf-c expression and is 
known to have basal characteristics. Cells were injected into the 4th mammary fat pad 
and allowed to form palpable tumors. The mice were treated twice weekly with 
intraperitoneal injections of clone 1 or isotype matched control antibody. Inhibiting 
epithelial PDGF-CC reduced tumor growth rate and at the endpoint, tumor size was 
30% less in the treated cohort. These tumors also had a reduced vessel number, as 
assessed by podocalyxin staining.  
  25 
 
We conclude that high epithelial PDGF-CC expression in breast cancer is associated 
with a shorter survival. Epithelial PDGF-CC was found to be an independent 
prognostic marker. Inhibiting PDGF-CC signaling in our mouse model reduced the 
tumor growth rate using a monoclonal antibody as a mono-therapy. We suggest that 
PDGF-CC is a marker of basal-like breast cancer and that inhibiting PDGF-CC 
signaling in basal-like breast cancer may be a novel therapy option in a form of breast 
cancer currently lacking targeted therapy. In addition, epithelial PDGF-CC expression 
represents an independent prognostic factor of survival.  
 
Further investigations to dissect the role of PDGF-CC expression in breast cancer are 
warranted. The molecular mechanism needs to be investigated. In light of our previous 
results with OPN expression increasing when PDGF-CC is expressed it would be 
interesting to investigate if OPN is involved in this system. High OPN was found to be 
a marker of poor overall survival in a meta-analysis in all tumors combined and also in 
breast, lung and prostate cancer (Weber et al., 2010). Investigating the metastatic 
pattern in light of PDGF-CC expression, especially if OPN is high in the PDGF-CC 
expressing tumors, would also be interesting. OPN has been shown to promote CCL5 
expression in mesenchymal stromal cells and that the abundance of these cells is 
increased at the site of metastasis in their mouse model by an OPN dependent 
mechanism (Mi et al., 2011).  Finally, OPN was found among the up-regulated stromal 
genes predicting poor outcome in breast cancer (Finak et al., 2008). 
 
We are currently studying the effect of genetic ablation of PDGF-CC in a genetically 
modified mouse model of breast carcinoma. In short, PDGF-CC deficient mice were 
crossed with the MMTV-PyMT breast tumor model. Initial characterization of this 
model revealed a delayed onset of tumor growth and over 50 % reduction in tumor size 
in mice heterozygote for pdgf-c.  
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3.3 PAPER III: ADAPTATION TO IMPAIRED TUMOR ANGIOGENESIS IN 
ENDOGLIN-DEFICIENT MICE IS PARALLELED BY A WEAKENED 
ENDOTHELIAL BARRIER TO METASTATIC DISSEMINATION.  
The introduction of antiangiogenic therapies into the clinic did not meet the high 
expectations on increased overall survival predicted from preclinical studies. The 
common theme of all introduced angiogenic-targeting therapies are inhibition of VEGF 
signaling. However, recent preclinical trials have described several means of resistance 
to the VEGF inhibition (Bergers and Hanahan, 2008; Casanovas et al., 2005; Ebos et 
al., 2009a; Ebos et al., 2009b; Paez-Ribes et al., 2009). 
 
Are these resistance mechanisms exclusive to anti-VEGF therapy? Could similar 
mechanisms be identified when manipulating other signaling pathways involved in 
angiogenesis in tumors? High expression of endoglin in tumor endothelial cells has 
been reported and high endoglin expression correlates with poor survival (Charpin et 
al., 2004; Dales et al., 2004; Kumar et al., 1999; Martone et al., 2005; Takahashi et al., 
2001b; Wikstrom et al., 2002). Consequently, we wanted to investigate the role of the 
TGF-β co-receptor endoglin in tumor angiogenesis. 
 
We started our investigations by characterizing the expression of endoglin in the 
prototypical genetically engineered mouse RIP1-Tag2 model that develop pancreatic 
neuroendocrine tumors in a multistep process in a predictable manner. Endoglin was 
shown to be expressed by the tumor vessels in this model and exhibited a peak in 
expression in the angiogenic lesions. The RIP1-Tag2 mouse was crossed with endoglin 
haploinsufficient mice. Initial characterization of the tumor development in the 
deficient mice revealed a reduction in number of angiogenic islets and number of 
tumors but the tumor volume was similar.  This indicates that even though fewer 
lesions progressed to the angiogenic and tumor stage, the ones that did evade the 
angiogenic insult displayed a growth aggressive phenotype. There was no difference in 
vessel density assessed by podocalyxin nor perfused vessels when using lectin.  
 
To confirm the phenotype we used a syngeneic breast tumor cell line, EO771, that we 
injected orthotopically in endoglin haploinsufficient mice and controls. Endoglin 
deficienty did not affect the growth pattern of these tumors indicating that they were 
intrinsically resistant. Similar to the RIP1-Tag2 model, there was no change in vessel 
density. In addition, we used an inducible endothelial cell specific endoglin knockout 
mouse model injected subcutaneously with LLC cells. Initial growth impairment was 
recorded 6 days after injections but the tumors circumvented this and mice presented 
with similar tumor volumes at the end point. The vessel density showed a similar 
pattern, reduced in endoglin knockouts at 6 days but equal at the end point.  
 
We recorded an increase in micro- or macrometastases to the respective target organ in 
all three mice models. Thus the resistant tumors displayed an increased metastatic 
capacity.  
 
Next, we investigated whether concurrent treatment with VEGF inhibitors of endoglin 
hapolinsufficient mice bearing tumors would affect tumor growth, as the observed 
phenotype resembled the phenotype of VEGF inhibition. We selected a long treatment 
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schedule that would allow the tumors to become resistant to the anti-VEGF therapy. 
Interestingly, the combination of genetic endoglin deficiency and anti-VEGF treatment 
did not seem to induce resistance and mice presented with smaller tumors (RIP1-Tag2) 
or reduced tumor growth rate (EO771). This also translated into a decreased number of 
detected micrometastases to a similar level as seen without angiogenic insult.  
 
There are several possible explanations to the increased number of micrometastases. It 
could be the tumor cells that acquire increased ability to metastasize through up-
regulation of e.g. migratory or invasive genes or changes in the endothelial cells 
facilitating transmigration of tumor cells. We did not detect any differences in the 
tumor cells. We therefore turned our interest to the endothelial barrier function. 
Knockdown of endoglin in the endothelial cell line bEND3.1 resulted in an increased 
tumor cell transmigration of cells from RIP1-Tag2 tumors (βTC-3) and EO771 cells 
over the endothelial cell barrier in a transwell assay. We detected an increase in 
transcripts from circulating tumor cells in blood from endoglin haploinsufficient RIP1-
Tag2 mice suggesting enhanced transmigration of tumor cells also in vivo. We could 
not detect any difference in number of βTC-3 cells extravasating in the liver of 
endoglin deficient mice after tail vein injections. This implies that a change in the 
endothelial barrier of the tumors in RIP1-Tag2 mice is responsible for the increased 
metastatic potential when endoglin is ablated. However, when LLC cells injected in the 
tail vein in endothelial endoglin knockout mice an increase in number of lesions in the 
lung was detected. These, at first view contradictory results, may be explained by the 
distribution of endoglin expression in the respective organ, liver has very little endoglin 
expression while the lungs display high expression.  
 
We continued the investigations by looking at the vessels in the RIP1-Tag2 tumor 
model in closer detail. The expression pattern of the endothelial junctional protein 
CD31 was changed. The CD31 strongly positive vessels were reduced in endoglin 
deficient mice and in cases where CD31 appeared strong, the staining pattern was more 
diffuse not closely associated with the podocalyxin co-staining. To investigate if this 
reduction of an endothelial junctional marker was a sign of the endothelial cells loosing 
their identity through EndMT we stained tumors for α-SMA, a mesenchymal marker. 
α-SMA staining was strongly induced in some areas in endoglin deficient mice 
surrounding the vessels and also sometimes overlapping with the vessel markers 
podocalyxin and CD31. Increased abundance of α-SMA in association with or 
overlapping with vessel marker was also detected in EO771 tumors from endoglin 
deficient mice.  
 
We next isolated endothelial cells from RIP1-Tag2 tumors of each genotype and found 
the transcription factor twist up-regulated in endoglin deficient endothelium on the 
mRNA level. Twist is a key activator of EndMT. EndMT is characterized by loss of 
cell-cell junctions and acquisition of invasive and migratory properties. Concomitantly, 
endothelial markers such as CD31 is lost and mesenchymal markers like FSP-1 and α-
SMA are up-regulated (Potenta et al., 2008). Most knowledge about EndMT have been 
collected from developmental studies but one study show that a substantial proportion 
of CAFs was derived through EndMT in the B16 mouse melanoma model (Zeisberg et 
al., 2007). TGF-β signaling is a known inducer of EndMT (Potenta et al., 2008). We 
continued to investigate the EndMT phenotype of endothelial cells in vitro in the 
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context of endoglin signaling. Knock down of endoglin in bEND3.1 cells stimulated 
with TGF-β displayed an increase in the mesenchymal marker α-SMA and concurrent 
decrease of endothelial marker CD31 both on western blot and in immunostainings. 
Using the transwell assay system we showed that TGF-β stimulation of a MS1 
endothelial cell layer increased the transmigration of βTC-3 cells. In addition, knock 
down of CD31 also increased the transmigration of βTC-3 and EO771 cells. The 
increased transmigration of tumor cells suggest that induction of EndMT characteristics 
in endothelial cells induced changes that weakened the endothelial cell barrier.  
 
In conclusion, genetic ablation of endoglin expression only inhibited tumor growth 
transiently. The lesions adapted to the angiogenic insult and developed resistance. The 
resistance phenotype was associated with increased metastatic seeding to distant 
organs. Vessels in the tumor did go through EndMT rendering them more permissive to 
tumor cell transmigration enabling the metastatic phenotype. In addition, combining 
two angiogenic insults, VEGF inhibition and genetic ablation of endoglin maintain the 
tumors sensitive to anti-VEGF therapy resulted in reduced tumor volume and decreased 
seeding of distant metastases. Our results indicate that combining two different 
antiangiogenic insults, at least, prolongs time until the tumors show signs of resistance 
with regard to tumor growth and metastatic capacity. This suggests that a combination 
of antiangiogenic therapies should be investigated in the human setting to avoid the 
induction of resistant tumors and possibly increase the overall survival. We also 
identified EndMT induced by genetic ablation of endoglin singling having important 
function in the tumor vessel integrity and hence the metastatic process in tumors.  
 
The knowledge about EndMT is still rather limited and especially in tumor biology. 
However, TGF-β signaling has been shown to be important in EndMT (Potenta et al., 
2008). It was recently shown that TGF-β mediated ALK5 dependent signaling induced 
by shear stress in endothelial cells that were sensitized by the lack of cilia induced 
EndTM (Egorova et al., 2011). This may suggest that the EndMT we detect are a result 
of increased ALK5 signaling due to the lack of endoglin modulation of signaling (ten 
Dijke et al., 2008).  
 
EndMT may be the explanation to the noted increase in α-SMA expressing cells in the 
vicinity of vessels in a subset of tumors after anti-VEGF therapy inducing resistance 
(Franco et al., 2011a; Helfrich et al., 2010). This phenomenon has also been described 
in RIP1-Tag2 mice deficient for neural cell adhesion molecule (NCAM) (Xian et al., 
2006), implicating reduction of NCAM in EndMT.  
 
Aberrant endoglin has previously been correlated with increased metastasis in human 
studies (Takahashi et al., 2001b). In these cases soluble endoglin have been elevated 
which is suggested to act as an inhibitor of cell surface bound endoglin modulation of 
signaling (Hawinkels et al., 2010). HHT1 patients are deficient in endoglin and our 
endoglin heterozygot mice mimic their disease (Shovlin, 2010). Our result suggest that 
this patient group, in case of tumor development, would have an increased risk of 
metastatic disease and would benefit from anti-VEGF therapy. We propose that further 
studies are warranted regarding the effect of combining inhibition of different 
antiangiogenic signaling pathways simultaneously in order to induce a sustainable 
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antiangiogenic effect without the development of resistance resulting in an increase in 
overall survival.  
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3.4 PAPER IV: GENETIC AND PHARMACOLOGICAL TARGETING OF 
ACTIVIN RECEPTOR-LIKE KINASE 1 IMPAIRS TUMOR GROWTH 
AND ANGIOGENESIS.  
TGF-β and BMP-9 share a common TGF-β type I receptor, ALK1. Contradictory 
reports regarding the inhibitory or stimulating effect TGF-β and BMP-9 have on 
angiogenesis prompted us to investigate the effect of modulating this system in vivo, 
with the aim of investigating this system as a potential pathway to interfere with tumor 
angiogenesis.  
 
We started by characterizing the expression of ligands and receptors of the tumors of 
RIP1-Tag2 mice. The expression, assessed by quantitative RT-PCR, of TGF-β and 
BMP-9 increased during the tumorigenic process and ALK1 expression was increased 
in the angiogenic lesions. Histological examination revealed that both ligands were 
expressed predominantly by the tumor cells. ALK1 expression was restricted to the 
endothelial cells in vessels and was not present in pericytes.  
 
Mice lacking one copy of the alk1 gene were bred with RIP1-Tag2 mice to investigate 
the effect of genetically ablated ALK1 signaling during tumorigenesis. The number of 
angiogenic lesions was reduced and this translated into fewer tumors and lower additive 
tumor volume.  Thus, the angiogenic switch in the ALK1 deficient mice was retarded 
translating into slow down of the tumorigenic process. When assessing the tumor 
vascular density it was reduced and also the density of perfused vessels was lower in 
the ALK1 deficient mice.  
 
We assessed the option of using ALK1 inhibition as a therapeutic target using an 
ALK1-Fc fusion protein, RAP-041. In vitro studies revealed that RAP-041 was a potent 
inhibitor of BMP-9. The fusion protein also affected VEGF and FGF-2 induced 
angiogenesis in the matrigel plug assay reducing the ingrowth of vessels. When RIP1-
Tag2 mice were treated with RAP-041, tumor volume was reduced in a dose dependent 
manner. A two week long treatment schedule, started both at early (at 10 weeks) and 
late (at 12 weeks) stages of disease, showed that the inhibitor blocked tumor growth. 
The treated animals presented with a tumor burden comparable to a control cohort 
sacrificed at the initiation of treatment. Histological characterization of treated mice or 
controls, regardless of tumor stage, revealed a reduced vessel density after the treatment 
as shown by CD31 staining and also the perfused vessel density was lower. Hence, 
RAP-041 was able to inhibit tumor angiogenesis in our mouse model resulting in 
increased apoptosis that augmented tumor growth.  
 
The molecular mechanism was investigated in vitro, ex vivo and in vivo. The effect of 
either ligand alone or in combination was studies in three different cell lines. The 
combination of TGF-β and BMP-9 stimulated endothelial cell proliferation when 
VEGF was present but either ligand alone reduced the proliferation. Using the matrigel 
plug assay with baseline presence of both VEGF and FGF-2 and variable presence of 
TGF-β or BMP-9 or the combination in vivo confirmed the phenotype of the in vitro 
experiments. The combination of ligands improved the ingrowth of vessels. This effect 
was blocked by RAP-041. To further strengthen the observation that the combination 
induced angiogenesis while either ligand alone had the opposite effect an ex vivo 
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sprouting angiogenesis assay was designed. In short, angiogenic islets from RIP1-Tag2 
mice were isolated and seeded onto matrigel plugs containing endothelial cells, the 
ligands of interest were added to the culturing media. It is known that angiogenesis in 
the RIP1-Tag2 tumors are dependent on VEGF and the angiogenic islets contain VEGF 
(Inoue et al., 2002). Again the combination induced a positive response with 
endothelial cell sprouting and migration while either ligand alone or addition of RAP-
041 negated the effect. Thus, the combination of TGF-β and BMP-9 has a synergistic 
effect enhancing angiogenesis prompted by VEGF and FGF-2.  
 
We also analysed the expression pattern of genes with pro-angiogenic effects 
downstream of ALK1 (ID1 and ID3) and ALK5 (PAI-1) signaling by quantitative RT-
PCR. In tumors from RIP1-Tag2 mice that were either ALK1 heterozygote or treated 
with RAP-041, expression levels of all targets genes were down-regulated. In line with 
this, endothelial cells in culture up-regulated expression of PAI-1 in response to the 
combination of TGF-β and BMP-9, both on RNA and protein level. Interestingly, the 
synergistic effect of both ligands required both ALK1 and ALK5 receptors as specific 
inhibition of each receptor with the combination of both ligands reduced the expression 
of the target gene PAI-1. Assessing activation of upstream signaling pathways 
suggested that SMAD2 was involved. In conclusion, target genes downstream of both 
ALK1 and ALK5 were affected by reduction of ALK1 signaling through genetic or 
pharmacological targeting.  
 
Genetic ablation or pharmacological targeting of ALK1 demonstrates that tumor 
angiogenesis is reduced and tumor growth halted. Hence, targeting of ALK1 represents 
a valid therapeutic target of antiangiogenic therapy. We believe that some of the 
discrepancies reported in earlier studies of TGF-β family effects on angiogenesis might 
be explained by the presence or absence of unexpected or not studied receptors and/or 
ligands. Most likely, a correct delicate balance of both receptors and ligands affect the 
outcome of TGF-β family signaling in angiogenesis.  
 
The humanized form of RAP-041, ACE-041, and a monoclonal antibody are initiating 
clinical trials as antiangiogenic therapies in cancer. A phase 1 study is ongoing and 
preliminary results show that the ACE-041 is generally well tolerated when 
administered subcutaneously every three weeks. 4 out of 25 patients display stable 
disease lasting at least 6 cycles after previously having progressed on prior therapies 
(Bendell. et al., 2011). Our results suggest that this could be an effective treatment 
modality and we have not recorded any signs of development of resistance although 
this should be assessed using longer treatment periods. However, a word of caution in 
warranted. As our mechanistic studies revealed the surprising synergistic effect on 
angiogenesis by the combination of TGF-β and BMP-9 signaling it will be important to 
profile the ligand and receptor status of each patient ensuring the predicted treatment 
response.   
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4 FUTURE PERSPECTIVES  
 
The first chemotherapeutic agent, a primitive alkylating compound, was presented in 
1943. During the subsequent 15 years several of the compound classes we have today 
were developed. The first agents had some clinical benefit and remission in a subset of 
patients was achieved but patients often relapsed quite quickly. In the 1960s, the 
concept of cure by the use of chemotherapy started to emerge with the use of 
combination chemotherapeutic regimens (DeVita and Chu, 2008).  
 
Targeted therapies have been developed and used in the clinic from the late 1990s, with 
a monoclonal antibody trastuzumab (Herceptin) being the first introduced followed by 
a receptor tyrosine kinase inhibitor imatinib (Gleevec) in 2001. In light of the very early 
lessons of treating cancer with drugs it is not entirely surprising that the new targeted 
therapies have not met the great expectations of increased overall survival. The patients 
develop resistance to these agents. We and others suggest that the combination of 
several different agents will prove more successful. To achieve this we need to develop 
a much bigger toolbox of targeted therapies.  
 
To increase the targets, understanding of possible targets and the response to such 
therapies, more intricate studies are required. As an example, further characterization of 
the different CAFs populations and deeper understanding of the angiogenic process 
would most likely be highly rewarding. Many of the pathways identified today may 
have redundant capacity and possibly also display phenotypic changes that have to be 
investigated in detail. Crucial to these studies are the use of proper and complex model 
systems. Another important feature of targeted therapies will be the selection of the 
appropriate patients that will benefit from the therapy based on expression of different 
signaling molecules and/or receptors.   
 
I find it probable that several pathways need to be targeted in conjunction to avoid 
resistance development and that these pathways need to be selected for each patient 
individually based on their specific molecular profile. This will pose huge problems for 
future clinical trials. The design of clinical trials must be altered radically for the 
introduction of new agents meant to be used in combinations on the market. Each 
component alone is likely to have only minor clinical efficacy on its own but together 
they can act in concert to produce clinical benefit. 
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